
Anixa Biosciences Reports Stable Disease in Ovarian Cancer CAR-T Trial
A patient in Anixa Biosciences’ Phase 1 clinical trial for recurrent ovarian cancer has achieved stable disease three months after treatment. This milestone, occurring in the study’s fifth dose cohort, marks the first time the novel liraltagene autoleucel therapy has demonstrated such a response in a human subject.

























